Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Therapy: Clinical

Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

Bryan J. Schneider, Manish A. Shah, Kelsey Klute, Allyson Ocean, Elizabeta Popa, Nasser Altorki, Michael Lieberman, Andrew Schreiner, Rhonda Yantiss, Paul J. Christos, Romae Palmer, Daoqi You, Agnes Viale, Pouneh Kermani and Joseph M. Scandura
Bryan J. Schneider
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bryansch@med.umich.edu
Manish A. Shah
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelsey Klute
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allyson Ocean
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeta Popa
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nasser Altorki
Department of Thoracic Surgery, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Lieberman
Department of Surgery, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Schreiner
Department of Pathology, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhonda Yantiss
Department of Pathology, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J. Christos
Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romae Palmer
Clinical Trials Office, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daoqi You
Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnes Viale
Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pouneh Kermani
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph M. Scandura
Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.Division of Regenerative Medicine, Department of Internal Medicine; Weill Cornell Medical College, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-16-1896
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

DOI 
https://doi.org/10.1158/1078-0432.CCR-16-1896
PubMed 
27836862

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received July 31, 2016
  • Revision received October 5, 2016
  • Accepted October 25, 2016
  • Published first November 10, 2016.

Article Versions

  • Previous version (November 10, 2016 - 10:00).
  • You are currently viewing a Previous version of this article (March 20, 2017 - 06:58).
  • View the most recent version of this article
Copyright & Usage 
©2016 American Association for Cancer Research.

Author Information

  1. Bryan J. Schneider1,*,
  2. Manish A. Shah1,
  3. Kelsey Klute1,
  4. Allyson Ocean1,
  5. Elizabeta Popa1,
  6. Nasser Altorki2,
  7. Michael Lieberman3,
  8. Andrew Schreiner4,
  9. Rhonda Yantiss4,
  10. Paul J. Christos5,
  11. Romae Palmer6,
  12. Daoqi You7,
  13. Agnes Viale7,
  14. Pouneh Kermani1, and
  15. Joseph M. Scandura1,8
  1. 1Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
  2. 2Department of Thoracic Surgery, Weill Cornell Medical College, New York, New York.
  3. 3Department of Surgery, Weill Cornell Medical College, New York, New York.
  4. 4Department of Pathology, Weill Cornell Medical College, New York, New York.
  5. 5Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
  6. 6Clinical Trials Office, Weill Cornell Medical College, New York, New York.
  7. 7Memorial Sloan-Kettering Cancer Center, New York, New York.
  8. 8Division of Regenerative Medicine, Department of Internal Medicine; Weill Cornell Medical College, New York, New York.
  1. ↵*Corresponding Author:
    Bryan J. Schneider, C411 Med Inn Building, 1500 East Medical Center Drive, SPC 5848, Ann Arbor, MI 48019. Phone: 734-647-8921; Fax: 734-647-8792; E-mail: bryansch{at}med.umich.edu

Next
Back to top

Published OnlineFirst March 20, 2017
doi: 10.1158/1078-0432.CCR-16-1896

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
Bryan J. Schneider, Manish A. Shah, Kelsey Klute, Allyson Ocean, Elizabeta Popa, Nasser Altorki, Michael Lieberman, Andrew Schreiner, Rhonda Yantiss, Paul J. Christos, Romae Palmer, Daoqi You, Agnes Viale, Pouneh Kermani and Joseph M. Scandura
Clin Cancer Res March 20 2017 DOI: 10.1158/1078-0432.CCR-16-1896

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
Bryan J. Schneider, Manish A. Shah, Kelsey Klute, Allyson Ocean, Elizabeta Popa, Nasser Altorki, Michael Lieberman, Andrew Schreiner, Rhonda Yantiss, Paul J. Christos, Romae Palmer, Daoqi You, Agnes Viale, Pouneh Kermani and Joseph M. Scandura
Clin Cancer Res March 20 2017 DOI: 10.1158/1078-0432.CCR-16-1896
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Andecaliximab alone and combined in gastric/GEJ cancer
  • Tumor growth inhibition-OS model for atezolizumab in NSCLC
  • Impact of baseline tumor size on outcomes in melanoma
Show more Cancer Therapy: Clinical
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement